Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Jul 09, 2020 10:12am

243 Views

Post# 31244755

RE:Echelon

yup. Conservative: $1.4 Target: $1.7 High: $2

Amigo11 wrote: Out today re-iterating Buy -no change in PT at $1.40-ascribed staus of top pick-stock "dramatically" underpriced.Easy to say they had to support it with research as they are the underwriter of choice but they make some good points about medium term partnership and basically back up the "positive" posts of this boards Longies !

Bullboard Posts

Eminent acquires promising Nevada gold project